Skip to content

Change in AP at other companies

Pfizer logo
PfizerPFE
-$117.25M+54.2%
Amgen logo
AmgenAMGN
$571M+14.9%
Janux Therapeutics logo
Janux TherapeuticsJANX
-$1.61M+1.5%
Allogene Therapeutics logo
Allogene TherapeuticsALLO
$663K+297%
Vor Biopharma logo
Vor BiopharmaVOR
-$9.1M-563%
Design Therapeutics, Inc. logo
Design Therapeutics, Inc.DSGN
-$2.51M-734%

Other financials

Income statement

See full
Revenue$10.3M-79.9%
Operating income-$19.7M-187%
Net income-$18.2M-178%
EPS (diluted)-$0.10-137%

Balance sheet

See full
Cash & equivalents$28.8M-39.4%
Total debt$2.9M-65.0%
Total equity$319.9M+1,177%
Total assets$359.4M+265%

Cash flow

See full
Operating cash flow-$25.5M-21.4%
CapEx--100%
Free cash flow-$25.5M-20.7%

Valuation

See full
Market cap$711.89M+94.8%
Enterprise value$685.92M+110%
P/S20×+17.6×

Profitability

See full
Operating margin-181.9%-206pp
Net margin-166.4%-195pp
FCF margin-225.6%-334pp

Returns & leverage

See full
Return on equity-34.3%
Debt / equity-0.3×
Current ratio10.4×+8.7×

Where this comes from

Reported directly by CytomX Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccountsPayable.

The official record: CytomX Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about CytomX Therapeutics's change in ap.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is CytomX Therapeutics's change in AP?
CytomX Therapeutics (CTMX) reported change in AP of $67K in Q1 2026.
How has CytomX Therapeutics's change in AP changed year-over-year?
CytomX Therapeutics's change in AP increased by 108.3% year-over-year, from -$804K to $67K.
What does change in AP mean?
Increase or decrease in amounts owed to suppliers — a key working capital component affecting operating cash flow.